Login

Healthcare

00:00:00
Pharmaxis welcomes positive interim data for Phase 2 cancer trial - Gary J Phillips B Pharm MBA - Chief Executive Officer, Pharmaxis Ltd
00:00:00
Pharmaxis Ltd expects review of Bronchitol NDA to be completed by mid-2020 - Gary J Phillips B Pharm MBA - Chief Executive Officer, Pharmaxis Ltd
00:00:00
OptiBiotix secures exclusive manufacturing agreement for CE marked SlimBiome - Stephen Patrick O'Hara CEO / Founder, OptiBiotix Health
00:00:00
OptiBiotix Health delighted to launch range in India through Apollo - Stephen Patrick O'Hara CEO / Founder, OptiBiotix Health
00:00:00
Onconova Therapeutics featured on Worldwide Business - Dr. Steven Fruchtman, CEO, Onconova Therapeutics Inc
00:00:00
ONCIMMUNE HOLDINGS PLC - Strategy Update - Martin Gouldstone Chief Executive Officer, Oncimmune Holdings
00:00:00
Oncimmune "relaunch" already delivering results - Martin Gouldstone Chief Executive Officer, Oncimmune Holdings
00:00:00
ONCIMMUNE HOLDINGS PLC - Investor Presentation - Martin Gouldstone Chief Executive Officer, Oncimmune Holdings
00:00:00
Oncimmune's strategic pivot aims for robust growth in 2024 - Martin Gouldstone Chief Executive Officer, Oncimmune Holdings
00:00:00
Francois Martelet, CEO, Oasmia Pharmaceutical
00:00:00
Aram Mangasarian , CEO, NOXXON Pharma
00:00:00
Interview with Aram Mangasarian, CEO of NOXXON
00:00:00
Aram Mangasarian , CEO, NOXXON Pharma
00:00:00
Noxxon CEO discusses partners and cancer combinations - Aram Mangasarian , CEO, NOXXON Pharma
00:00:00
Noxopharm hails new Sofra™ drug inflammation results - Dr Gisela Mautner Chief Executive Officer and Managing Director, Noxopharm Ltd
00:00:00
Noxopharm details science-driven strategy in new investor presentation - Dr Gisela Mautner Chief Executive Officer and Managing Director, Noxopharm Ltd

© 2026 Nehu